BlackRock Inc. decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.0% in the 4th quarter, Holdings Channel reports. The firm owned 18,004,610 shares of the biopharmaceutical company’s stock after selling 1,352,721 shares during the period. BlackRock Inc. owned approximately 0.08% of Alexion Pharmaceuticals worth $2,153,171,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of ALXN. Valeo Financial Advisors LLC bought a new position in Alexion Pharmaceuticals in the 3rd quarter worth about $147,000. Dupont Capital Management Corp bought a new position in Alexion Pharmaceuticals in the 3rd quarter worth about $156,000. BT Investment Management Ltd bought a new position in Alexion Pharmaceuticals in the 3rd quarter worth about $165,000. Beacon Investment Advisory Services Inc. bought a new position in Alexion Pharmaceuticals in the 3rd quarter worth about $201,000. Finally, Invictus RG bought a new position in Alexion Pharmaceuticals in the 3rd quarter worth about $202,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.
In related news, EVP John B. Moriarty sold 3,363 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $115.70, for a total transaction of $389,099.10. Following the completion of the sale, the executive vice president now directly owns 71,400 shares of the company’s stock, valued at $8,260,980. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 1,774 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $206,333.94. Following the sale, the senior vice president now directly owns 47,212 shares of the company’s stock, valued at $5,491,227.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,930 shares of company stock valued at $3,378,199. Company insiders own 4.35% of the company’s stock.
ALXN has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a research report on Tuesday, October 31st. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Citigroup reduced their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research note on Friday, February 9th. SunTrust Banks set a $172.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $152.77.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $120.47 on Friday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a market cap of $26,220.00, a P/E ratio of 61.15, a P/E/G ratio of 1.14 and a beta of 1.16. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same period in the prior year, the business earned $1.26 earnings per share. The business’s quarterly revenue was up 9.5% on a year-over-year basis. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/18/alexion-pharmaceuticals-inc-alxn-holdings-reduced-by-blackrock-inc.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.